Stock Monitor: AcelRx Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free research report on Orthofix International N.V. (NASDAQ: OFIX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=OFIX as the Company's latest news hit the wire. On March 22, 2018, the Company announced that the US Food and Drug Administration (FDA) 510(k) has cleared the Company's new internal fixation system, the G-Beam™ Fusion Beaming System, designed primarily for the treatment of Charcot foot. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), which also belongs to the Healthcare sector as the Company Orthofix Intl. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=ACRX
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Orthofix International most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=OFIX
The G-Beam devices can be implanted in the medial and lateral columns of the foot to provide alignment, stabilization and fixation.
G-Beam™ Fusion Beaming System was Developed to Treat Neuropathic Deformities Requiring Fusion of Medial/ Lateral Columns
The G-Beam™ Fusion Beaming System is designed to address the specific demands of advanced deformity and trauma reconstructions of foot and ankle applications. The system was developed for the treatment of neuropathic deformities requiring fusion of the medial and/or lateral columns, with or without corrective osteotomies as well as for joint fusions within the mid- and hindfoot. The G-Beam™ Fusion Beaming System consists of two different diameter implant ranges, designed for optimal implant selection for wide ranging patient anatomies, and an instrumentation including the dedicated G-Beam Sterilization Tray. The G-Beam™ Fusion Beaming System is designed with an instrumentation and technique that have been developed to simplify the surgery.
The System Will Allow Orthofix to Establish in Internal Fixation Segment of Charcot Treatment Options
Davide Bianchi, President of the Extremity Fixation business unit at Orthofix, mentioned that the G-Beam Fusion Beaming System is the next step in working towards the Company's objective of becoming a recognized premium solution provider in the Charcot and Diabetic foot market segments.
Davide added that this system will allow Orthofix to establish in the internal fixation segment of Charcot treatment options, while leveraging its existing product lines, like TrueLok™ and the TL-HEX™.
Orthofix Recently Secured FDA Approval for New PhysioStim™ Bone Growth Stimulators
On March 07, 2018, the Company received FDA and European CE Mark approvals for its next-generation PhysioStim™ bone growth stimulators. The PhysioStim™ devices provide a non-surgical treatment option for patients who have a nonunion fracture to an extremity that has shown no visible signs of healing. These Class-III medical devices use a pulsed electromagnetic field (PEMF) signal to induce a low-level electrical field at the fracture site which stimulates bone healing. These devices come in different models and are designed to anatomically fit the patient's body.
About Charcot Foot
Charcot foot is a condition causing weakening of the bones in the foot that can occur in people who have significant nerve damage (neuropathy). The bones are weakened enough to fracture, and with continued walking, the foot eventually changes shape. As the disorder progresses, the joints collapse, and the foot takes on an abnormal shape, such as a rocker-bottom appearance. Charcot foot is a serious condition that can lead to severe deformity, disability and even amputation. The symptoms of Charcot foot may include warmth to the touch, redness in the foot, swelling, pain, or soreness.
About Orthofix International N.V.
Established in 1980 and is headquartered in Lewisville, Texas, Orthofix is a diversified, global medical device company focused on musculoskeletal healing products and value-added services. The Company is comprised of four strategic business units: Biostim, Biologics, Extremity Fixation, and Spine Fixation.
Stock Performance Snapshot
March 23, 2018 - At Friday's closing bell, Orthofix International's stock was slightly down 0.80%, ending the trading session at $58.11.
Volume traded for the day: 96.91 thousand shares.
Stock performance in the last month - up 7.35%; previous three-month period - up 5.56%; past twelve-month period - up 48.77%; and year-to-date - up 6.23%
After last Friday's close, Orthofix International's market cap was at $1.07 billion.
Price to Earnings (P/E) ratio was at 69.68.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
